Our studies initially utilized genetically matched lung cancer cells A549 (KRAS G12S) and its taxane-resistant derivative A549TR cells, EGFR mutant PC-9 cells and its osimertinib-resistant derivative PC-9-OR cells, as well as mouse KP7B cells that carry KRAS G12D/p53 deletion and represent a clinically relevant model of lung cancer. This evidence concerns the gene KRAS and lung cancer.